NCT05465213 - Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF) | Crick | Crick

Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)

N/ACompletedNCT05465213

AstraZeneca283 enrolled

Overview

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). On May 5, 2020, the US Food and Drug Administration (FDA) announced the approval of dapagliflozin for heart failure with reduced ejection fraction (HFrEF), regardless of whether the patient has diabetes. Subsequently, there have been additional approvals for this indication by regulatory authorities across the globe." Real-world observational data are necessary to describe dapagliflozin use in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and HRQoL.

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). On May 5, 2020, the US Food and Drug Administration (FDA) announced the approval of dapagliflozin for heart failure with reduced ejection fraction (HFrEF), regardless of whether the patient has diabetes. Subsequently, there have been additional approvals for this indication by regulatory authorities across the globe." Real-world observational data are necessary to describe dapagliflozin use in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and HRQoL. EVOLUTION-HF will help obtaining relevant insights from clinical practice through the analysis of detailed data on heart failure symptoms/severity for patients receiving dapagliflozin in real-world setting. Study aims are to describe the characteristics of patients newly prescribed dapagliflozin for the treatment of HFrEF, to provide early insights into real-world dapagliflozin treatment patterns, and to describe patients-reported outcomes, medication adherence and work productivity losses in these patients. This observational, longitudinal cohort study will include patients with a physician diagnosis of HFrEF who are initiated on dapagliflozin in clinical practice. The study will include 2 cohorts of patients: one fully retrospective and one prospective cohort, in which patient-reported outcomes (PROs) including quality of life will be collected

Study Type

OBSERVATIONAL

Outcomes

Primary Outcomes

Time to dapagliflozin treatment discontinuation

Time from dapagliflozin treatment initiation until the time at which participants stop taking the medication for any reason.

Time frame: Baseline to 12 months

Number of reasons for dapagliflozin treatment discontinuation

Number of reasons for dapagliflozin treatment discontinuation as noted by a health care professional will be extracted and described as the number and proportion of participants who have discontinued dapagliflozin according to each reasons presented.

Time frame: Baseline to 12 months

Proportion of reasons for dapagliflozin treatment discontinuation

Proportion of reasons for dapagliflozin treatment discontinuation as noted by a health care professional will extracted and described as the number and proportion of participants who have discontinued dapagliflozin according to each reasons presented.

Time frame: Baseline to 12 months

Number of dapagliflozin treatment changes

The number of participants who switch to another HF medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of dapagliflozin treatment changes

The percentage of participants who switch to another HF medication other than dapagliflozin.

Time frame: Baseline to 12 months

Number of dapagliflozin treatment discontinuation

The number of participants who discontinued treatment with dapagliflozin.

Time frame: Baseline to 12 months

Percentage of dapagliflozin treatment discontinuation

The percentage of participants who discontinued treatment with dapagliflozin.

Time frame: Baseline to 12 months

Time to other HF medication discontinuation

Time from initiation of heart failure medication other than dapagliflozin until the time at which participants discontinued treatment with that medication.

Time frame: Baseline to 12 months

Number of other heart failure treatment initiation

The number of participants who initiate new heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of other heart failure treatment initiation

The percentage of participants who initiate new heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Number of other heart failure treatment dosage changes

The number of participants with dosage changes for heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of other heart failure treatment dosage changes

The percentage of participants with dosage changes for heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Number of other heart failure treatment discontinuation

The number of participants who discontinue treatment with heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of other heart failure treatment discontinuation

The percentage of participants who discontinue treatment with heart failure medication other than dapagliflozin.

Time frame: Baseline to 12 months

Time to glucose lowering medication discontinuation

Time from initiation of glucose lowering medication until the time at which participants discontinued treatment with that medication.

Time frame: Baseline to 12 months

Number of glucose lowering medication initiation

The number of participants who initiate new glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of glucose lowering medication initiation

The percentage of participants who initiate new glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Number of glucose lowering medication dosage changes

The number of participants with dosage changes for glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of glucose lowering medication dosage changes

The percentage of participants with dosage changes for glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Number of glucose lowering medication discontinuation

The number of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Percentage of glucose lowering medication discontinuation

The percentage of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.

Time frame: Baseline to 12 months

Secondary Outcomes

Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Summary scores will be examined at each assessment point during follow-up. For each of the assessment periods, descriptive statistics for the observed value, change from baseline and the 95% two-sided confidence interval for the mean change will be presented. The proportions of participants with overall health status classified as poor, fair, good, and excellent will be examined at each assessment point. Additionally, the proportions of participants who experience clinically meaningful changes in overall health status: improvement (≥5 point increase), deterioration (≥5 point decrease), and stable (\<5 point increase or decrease) will be examined at each assessment point. Only applicable to Prospective cohort.

Time frame: Measured at 3, 6 and 12 months

Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire

The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviours occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. The MARS-5 has been shown to be reliable and valid across a variety of health conditions, including cardiovascular and pulmonary diseases. Only applicable to Prospective cohort.

Time frame: Measured at 3, 6 and 12 months

Absolute change from baseline in Work Productivity and Activity Impairment (WPAI) score

The WPAI is a validated instrument to measure impairments in paid and unpaid work and activities. It measures absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness) as well as the impairments in unpaid activity because of health problems during the past seven days. It has been validated to quantify work impairments for numerous diseases such as asthma, psoriasis, irritable bowel syndrome, and Crohn's disease, but has not yet been validated for use in heart failure participants. Scores will be derived from the overall work impairment at each timepoint and then changes of from baseline will be reported. Only applicable to Prospective cohort.

Time frame: Measured at 3, 6 and 12 months